Commentary · 27 May 2026
Conference abstractPublished 12 Oct 2017
WHY CLINICAL TRIALS SHOW THAT STRICT GLUCOSE REGULATION DOES NOT PREVENT DIABETIC COMPLICATIONS IN T2D: EVIDENCE SUPPORTING AN ALTERNATIVE HYPOTHESIS FOR PATHOGENESIS
Colorado State University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of Problem: A meta-analysis of clinical trials with 34,533 T2D patients shows that intensive lowering of glucose levels does not prevent neuropathy, retinopathy, nephropathy, cardiovascular death, nor excess mortality. Exposing patients to adverse effects from unbeneficial drugs is unjustified, yet remains standard therapy. An alternative hypothesis for pathogenesis of diabetic complications is greatly needed to develop meaningful rational therapies. Methodology & Theoretical Orientation: Following discovery that insulin and insulin-like growth factors (IGFs) are neurotrophic factors, the inter-related hypotheses were developed that loss of insulin and IGF activities is the dominant cause of diabetic neuropathy, and that replacement of such activities should ameliorate diabetic complications irrespective of unabated hyperglycemia. These hypotheses were tested by infusing IGFs, insulin, or their combination into diabetic rats to determine whether neuropathy is alleviated under conditions in which hyperglycemia is not prevented. Conclusion & Significance: IGF gene expression is reduced in peripheral nerves, brain and spinal cord in diabetes. Replacement IGF infusion prevented impaired sensory and motor nerve regeneration, hyperalgesia, abnormal ultrastructure in autonomic axons, loss of epidermal nerve fiber density, and poor gastric wound healing, but did not diminish hyperglycemia. To study mechanism, insulin and/or IGF was infused into diabetic rat brains under conditions that did not reduce hyperglycemia. A decrease in total mRNA, protein, and DNA levels was associated with brain atrophy and impaired learning/memory in diabetic rats. Insulin and IGF i.c.v. infusion prevented all of these disturbances despite unabated hyperglycemia. Insulin and IGFs are master switches controlling the levels of hundreds of proteins in tissues; loss of protein regulation, not hyperglycemia, is proposed as the most likely pathogenic cause for diabetic complications. Governments should manufacture clinical grade IGF (off-patent). Clinical trials are urgently needed to test insulin/IGF therapy.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pancreatic Disorders & Therapy.
Short communication · 27 May 2026
Immunometabolic Interactions in Pancreatic Disease: Crosstalk Between Energy Dysregulation, Immune Activation, and Tissue Dysfunction
Commentary · 27 May 2026
Microvascular Dysfunction in Pancreatic Disorders: Endothelial Injury, Perfusion Failure, and Tissue Consequences
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPancreatic Disorders & Therapy
- SubjectGastroenterology & Hepatology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Douglas N Ishii”
